AD 203
Alternative Names: AD-203Latest Information Update: 24 Jan 2023
Price :
$50 *
At a glance
- Originator Addpharma
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Gastritis
Most Recent Events
- 31 Dec 2020 Registered for Gastritis (In the elderly, In adults) in South Korea (unspecified route) (Addpharma website, January 2023)
- 17 Dec 2020 AD 203 is available for licensing as of 17 Dec 2020. http://www.addpharma.co.kr/
- 01 Jul 2020 Preregistration for Gastritis (In adults, In the elderly) in South Korea (unspecified route) (Addpharma pipeline, December 2020)